Clinical Trials · NCT07112872
A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 330
- Start date
- Aug 2025
- Locations
- 46 sites, 4 countries
- Primary endpoint
- RO7795081 vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30